Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

NCT07256210 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic T-cell Leukemia
Mixed Phenotype Acute Leukemia

Interventions

BIOLOGICAL: Donor-derived Natural Killer Cell

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology